1-(2-{2-[2-(2-{2-[2-(2-Methoxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethoxy)-dodecane | 63425-08-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(2-{2-[2-(2-{2-[2-(2-Methoxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethoxy)-dodecane
• 英文别名: 1-[2-[2-[2-[2-[2-[2-(2-Methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]dodecane
• CAS: 63425-08-1
• 化学式: C₂₇H₅₆O₈
• 分子量: 508.737
• InChiKey: ZMFHDFYSZZTLOL-UHFFFAOYSA-N

物化性质

• 沸点：
  542.9±45.0 °C(Predicted)
• 密度：
  0.968±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  35
• 可旋转键数：
  32
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  73.8
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  四聚乙二醇单月桂醚 在 sodium hydride 作用下， 以 四氢呋喃 、 mineral oil 为溶剂， 反应 3.0h， 生成 1-(2-{2-[2-(2-{2-[2-(2-Methoxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethoxy)-dodecane
  参考文献：
  名称：

  Application of Monodisperse PEGs in Pharmaceutics: Monodisperse Polidocanols

  摘要：

  Polydisperse PEGs are ubiquitously used in pharmaceutical industry and biomedical research. However, the monodispersity in PEGs may play a role in the development of safe and effective PEGylated small molecular drugs. Here, to avoid the polydispersity in polidocanol, the active ingredient in a clinically used drug, a macro cyclic sulfate-based strategy for the efficient and scalable synthesis of monodisperse polidocanols, their sulfates, and their methylated derivatives, was developed. TLC and HPLC analysis indicated a complex mixture in regular polidocanol and high purifies in monodisperse polidocanols and their derivatives. Assay on HUVEC, L929, and HePG2. cells showed-that monodisperse polidocanols have much higher cytotoxicity and safety than that of regular polidocanol. It was found that the monodispersity of PEGs in polidocanols is crucial for achieving the optimal therapeutic results. Therefore, based on this case study, it would be beneficial to optimize PEGylated small molecular drugs with monodisperse PEGs in pharmaceutical research and development.

  DOI：

  10.1021/acs.molpharmaceut.7b00496

文献信息

• Supercritical fluid chromatography/mass spectrometry using a quadrupole mass filter/quadrupole ion trap hybrid mass spectrometer with external ion source
  作者：J. David. Pinkston、Thomas E. Delaney、Kenneth L. Morand、R. Graham. Cooks

  DOI：10.1021/ac00038a013

  日期：1992.7.15

  The combination of capillary supercritical fluid chromatography (SFC) and ion trap mass spectrometry using an external, differentially-pumped ion source is described. This was accomplished using a capillary SFC instrument with direct, on-column injection, and a custom-built, direct-introduction interface to a quadrupole mass filter/ion trap (Q/trap). The hybrid mass spectrometer was equipped with a standard EI/CI ion source and operated with conventional ion trap detector (IM) electrodes and electronics. The hybrid mass analyzer system allows the ion trap to tolerate the high mobile-phase flow rates introduced to the ionization region of the mass spectrometer. The instrument was characterized and optimal operating conditions were determined with perfluorotributylamine, anthracene, and methyl docosanate. A sample of 80 fmol of anthracene provided a molecular ion peak with a S/N ratio of 20. Once the operating parameters were optimized, two less volatile mixtures were characterized. The first was a poly(dimethyisiloxane) with an average molecular weight of 770. The second was a derivatized surfactant for which the full structure was not known in advance but which was elucidated from the SFC/MS data.
• US4396776A
  申请人：——

  公开号：US4396776A

  公开（公告）日：1983-08-02
• Application of Monodisperse PEGs in Pharmaceutics: Monodisperse Polidocanols
  作者：Zeqiong Yu、Shaowei Bo、Huiyuan Wang、Yu Li、Zhigang Yang、Yongzhuo Huang、Zhong-Xing Jiang

  DOI：10.1021/acs.molpharmaceut.7b00496

  日期：2017.10.2

  Polydisperse PEGs are ubiquitously used in pharmaceutical industry and biomedical research. However, the monodispersity in PEGs may play a role in the development of safe and effective PEGylated small molecular drugs. Here, to avoid the polydispersity in polidocanol, the active ingredient in a clinically used drug, a macro cyclic sulfate-based strategy for the efficient and scalable synthesis of monodisperse polidocanols, their sulfates, and their methylated derivatives, was developed. TLC and HPLC analysis indicated a complex mixture in regular polidocanol and high purifies in monodisperse polidocanols and their derivatives. Assay on HUVEC, L929, and HePG2. cells showed-that monodisperse polidocanols have much higher cytotoxicity and safety than that of regular polidocanol. It was found that the monodispersity of PEGs in polidocanols is crucial for achieving the optimal therapeutic results. Therefore, based on this case study, it would be beneficial to optimize PEGylated small molecular drugs with monodisperse PEGs in pharmaceutical research and development.